Wellness Clinics: How the Rules Bend for Unapproved Peptides
Academic analysis examines how longevity clinics exploit regulatory gaps between TGA product oversight and AHPRA practitioner regulation.
The gap between therapeutic goods regulation and practitioner oversight is allowing wellness and longevity clinics to operate in a grey zone when supplying unapproved peptides, according to a legal analysis published by The Conversation on 21 July 2026.
The regulatory split
The analysis, authored by policy researcher Christopher Rudge, examines how Australia’s dual-regulator model creates space for clinics to supply unapproved compounds. The TGA regulates therapeutic goods but does not regulate clinicians. AHPRA and its national boards regulate health practitioners but do not regulate products. Where these two mandates meet, enforcement becomes more complex.
Under existing Australian regulations, doctors can prescribe unapproved products when there is a compelling clinical need backed by robust evidence. This mechanism, known as the Special Access Scheme or through authorised prescriber pathways, was designed to provide access for patients with serious conditions and limited treatment options. The Conversation analysis argues that longevity and wellness clinics are using these pathways to provide routine access to products without established therapeutic roles.
AHPRA confirms open investigations
AHPRA chief executive Justin Untersteiner, as quoted in the analysis, said the regulator was “concerned that some practitioners may be seeking to exploit the latest health trends by putting profits ahead of patients.” He described this conduct as “unacceptable” and confirmed AHPRA had open notifications regarding peptide prescribing and supply.
AHPRA stated it was being proactive in its response rather than only reacting to complaints, and had made clear its expectations around prescribing, compounding, and telehealth.
TGA advertising rule exploited
The TGA strictly forbids advertising prescription or unapproved products. However, as The Conversation reports, some clinics argue that promoting “peptide therapy” as a general service without naming specific compounds does not constitute advertising a prescription product. This interpretation is being tested. At least one Queensland clinic has removed and renamed its peptide therapy offering following media inquiry.
The Medical Republic also reported on 20 July 2026 that the TGA is escalating enforcement against unapproved peptide suppliers, with Medical Republic describing the TGA as having declared a “war” on unapproved products.
Market implications
The regulatory environment is tightening. Three developments are converging. First, the TGA has designated unapproved peptides as a priority compliance focus area, as confirmed by the Chief Medical Officer and TGA joint statement in June 2026. Second, AHPRA is actively investigating practitioners involved in peptide prescribing. Third, major national media outlets are scrutinising the longevity clinic model.
For researchers and procurement professionals, the key signal is that the regulatory frameworks governing who can prescribe what, and under which conditions, are under review. The current dual-regulator structure creates compliance ambiguity that is likely to be addressed through either legislative reform or strengthened inter-agency protocols.
What to watch
Three developments to monitor. First, the outcomes of AHPRA’s open investigations into peptide prescribing practices will set precedent for how practitioner regulation applies to longevity clinic models. Second, whether the TGA pursues enforcement action against clinics that advertise “peptide therapy” without naming specific compounds will clarify the advertising boundary. Third, the Senate inquiry into complementary medicines and research compounds, previously reported on PeptideWatch, may incorporate findings from the current enforcement activity.
Sources
- The Conversation, “How wellness clinics bend the rules to supply unapproved peptides and anti-ageing injections,” 21 July 2026: theconversation.com
- Medical Republic, “TGA escalates war on unapproved peptides,” 20 July 2026: medicalrepublic.com.au
- ABC News, “Telehealth peptide prescriptions expose longevity industry stretching the rules,” 20 July 2026: abc.net.au
For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.